Investment Rating - The report upgrades the investment rating of the company to "Buy" [4] Core Insights - The company achieved a revenue of 492 million RMB in 2025, representing a year-on-year growth of 31.7%, primarily driven by strong sales of six-axis collaborative robots and growth in embodied intelligence robotics [1] - The net loss for the company narrowed to 84 million RMB, a 12.4% improvement compared to the previous year, indicating a trend towards improved profitability [1] - The company significantly increased its R&D investment, reaching 115 million RMB in 2025, a 59.7% increase, with 39.3% allocated to the embodied intelligence sector [1] Revenue Breakdown - Six-axis collaborative robots are the core revenue growth engine, generating 302 million RMB in 2025, a substantial increase of 44.7%, accounting for 61.4% of total revenue [2] - Four-axis collaborative robots generated 93 million RMB, a slight decline of 3.0%, due to strategic adjustments in the educational product mix [2] - Composite robots achieved a revenue of 68 million RMB, reflecting a robust growth of 27.3% [2] - The embodied intelligence robotics business showed remarkable growth, with revenue reaching 20 million RMB, a significant increase of 418.8% compared to 3.9 million RMB in 2024 [2] Market Expansion - In the Chinese market, the company generated 249 million RMB in revenue, a growth of 44.4%, confirming its leading position [3] - The company is expanding its localized teams in Europe, integrating deeply into the European industrial manufacturing system [3] - In the Asia-Pacific market, the company's robotic products have successfully penetrated key automotive manufacturing processes, achieving large-scale applications [3] Strategic Developments - The company became the global leader in collaborative robot shipments in 2025, surpassing 100,000 units shipped [4] - The company launched a multi-form embodied intelligence platform, introducing various robots including humanoid and quadruped models [4] - The company has outlined three key development directions for embodied intelligence: scaling up wheeled humanoid robots in industrial settings, targeting 1,000 unit orders for the full-size humanoid robot Atom by 2026, and planning to promote quadruped robots in Q2 2026 with a target of 10,000 units [4] Financial Forecasts - Revenue forecasts for 2026 and 2027 have been raised to 696 million RMB and 976 million RMB respectively, with a new forecast for 2028 set at 1.37 billion RMB [4] - The company is expected to maintain a strong growth trajectory, supported by the rollout of embodied intelligence products and continued investment [4]

Investment Rating - The investment rating for Meituan-W (03690.HK) is "Outperform the Market" [6]. Core Views - The company's performance in Q4 2025 met expectations, with a projected recovery in profitability by 2026 [1][4]. - The core local business faced challenges, particularly in food delivery, while flash purchase maintained high growth [3][11]. - The company is expected to gradually improve its profitability in Q1 2026 due to a reduction in subsidies and an improvement in order structure [4][18]. Financial Performance Summary - In Q4 2025, Meituan reported a revenue of 920.96 billion CNY, a year-on-year increase of 4.1%, but an adjusted net loss of 150.80 billion CNY compared to a profit of 98.49 billion CNY in the same period last year [2][8]. - For the full year 2025, the company achieved a revenue of 3,648.55 billion CNY, representing an 8.1% increase, with an adjusted net loss of 186.48 billion CNY [2][8]. - The core local business revenue was 648.4 billion CNY in Q4 2025, down 1.1% year-on-year, with significant declines in delivery service and commission revenues due to increased competition and subsidy investments [3][11]. Future Projections - The revenue forecast for 2026 is 393.88 billion CNY, with an expected growth rate of 8.0% [5][21]. - Adjusted net profit is projected to be -17.76 billion CNY in 2026, improving to -0.94 billion CNY in 2027, and turning positive at 20.22 billion CNY in 2028 [5][21]. - The company anticipates a gradual recovery in profitability, with adjusted net profit margins expected to improve from -4.5% in 2026 to 4.1% in 2028 [20][21].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5]. Core Insights - The company achieved a revenue of 66.17 billion yuan in 2025, representing a year-on-year growth of 68.19%. The net profit attributable to shareholders was 2.33 billion yuan, up 179.37% year-on-year, with adjusted net profit reaching 2.69 billion yuan, an increase of 194.97% [2]. - The company continues to expand its store network rapidly, ending 2025 with 21,948 stores, a net increase of 7,554 stores throughout the year. The majority of new openings are in lower-tier cities, with a low closure rate of 1.2% [3]. - The gross margin for 2025 improved to 9.83%, up 2.21 percentage points year-on-year, driven by enhanced bargaining power with suppliers and supply chain optimization [4]. - The company expects continued profit growth in 2026, supported by scale effects, supply chain improvements, and reduced share-based payments [4]. Summary by Sections Financial Performance - In Q4 2025, the company reported revenue of 19.80 billion yuan, a 53.74% increase year-on-year, and a net profit of 770 million yuan, up 126.39% year-on-year [2]. - The annualized average revenue per store was 3.64 million yuan, a slight decrease of 2.7% year-on-year, indicating a narrowing decline compared to the first half of the year [3]. - The adjusted net profit margin for Q4 was 4.46%, reflecting a year-on-year increase of 1.50 percentage points [4]. Store Expansion and Operations - The company opened 2,431 new stores in Q4 2025, maintaining a strong opening pace despite the off-peak season [3]. - The closure of franchise stores was limited to 265 for the year, with only 54 closures in Q4, indicating strong operational performance [3]. Profitability and Margins - The adjusted net profit margin for the full year was 4.07%, an increase of 1.77 percentage points year-on-year, with Q4 margins also showing improvement [4]. - The company anticipates that the net profit margin will continue to rise in 2026 due to the combined effects of scale, supply chain optimization, and reduced share-based payments [4]. Future Projections - The company expects net profits of 3.56 billion yuan in 2026, 4.60 billion yuan in 2027, and 5.41 billion yuan in 2028, with growth rates of 53%, 29%, and 17% respectively [5]. - The report projects a price-to-earnings ratio of 19x for 2026, 15x for 2027, and 12x for 2028, reflecting a positive outlook on the company's valuation [5].

Investment Rating - The report maintains a "Buy" rating for TCL Electronics [1] Core Insights - TCL Electronics has entered into a partnership with Sony to establish a joint venture, with TCL holding a 51% stake and Sony holding 49%. This joint venture will take over Sony's home entertainment business, with an initial transaction value of approximately 75.399 billion Japanese yen, equivalent to about 3.78 billion Hong Kong dollars [1][2] - The collaboration is expected to enhance TCL's profitability significantly by leveraging Sony's advanced display technology and brand strength, particularly in the high-end market [1][3] - The financial projections indicate a positive growth trajectory for TCL, with expected net profits of 3.04 billion, 3.52 billion, and 4.12 billion Hong Kong dollars for the fiscal years 2026, 2027, and 2028, respectively, reflecting year-on-year growth rates of 20.4%, 17.1%, and 17.1% [3] Financial Summary - TCL's revenue for 2024 is projected at 99.322 billion Hong Kong dollars, with a growth rate of 25.75%. By 2028, revenue is expected to reach 164.382 billion Hong Kong dollars, with a compound annual growth rate of approximately 13.27% [7] - The company's net profit is forecasted to grow from 1.759 billion Hong Kong dollars in 2024 to 4.117 billion Hong Kong dollars in 2028, indicating a significant increase in profitability [7] - The price-to-earnings (P/E) ratio is projected to decrease from 9.10 in 2024 to 7.81 in 2028, suggesting an improvement in valuation as earnings grow [7]

Investment Rating - The report maintains a "Buy" rating with a target price of HKD 7.26, corresponding to 0.4x NAV for 2026 [10]. Core Views - The company has made significant non-cash impairment provisions and value reassessments in 2025, focusing on its core business and managing non-performing assets prudently. The management has also proposed an increased dividend plan and actively repurchased shares, reflecting confidence in the company's future [2][10]. - The revenue for 2025 is projected at RMB 173.425 billion, a year-on-year decrease of 9.74%, with a net loss of RMB 23.396 billion, representing a 437.97% increase in losses compared to the previous year. However, net profit forecasts for 2026-2028 have been adjusted to RMB 1.974 billion, RMB 2.912 billion, and RMB 4.139 billion, respectively, indicating significant recovery [10]. Financial Summary - Total revenue is expected to decline from RMB 192.142 billion in 2024 to RMB 173.425 billion in 2025, before gradually increasing to RMB 207.603 billion by 2028 [4]. - Gross profit is projected to decrease from RMB 54.730 billion in 2024 to RMB 51.067 billion in 2025, with a gradual recovery thereafter [4]. - The net profit is forecasted to be negative in 2025 at RMB (23.396) billion, but is expected to turn positive in 2026 with RMB 1.974 billion, and continue to grow in the following years [4]. - The company’s PE ratio is expected to improve from -6.75 in 2024 to 7.10 by 2028, indicating a potential recovery in profitability [12]. Segment Performance - The health segment reported revenue of RMB 48 billion in 2025, a year-on-year increase of 3.1%, with a net profit of RMB 14.34 billion, up 59.2% [10]. - The happiness segment saw a revenue decline of 15.6% to RMB 64.7 billion, resulting in a significant net loss of RMB 90.67 billion, primarily due to external pressures on consumer spending [10]. - The wealth segment's revenue was RMB 55.865 billion, with a slight increase of 1.4%, but it faced a net loss of RMB 141.73 billion, largely due to substantial impairment provisions [10]. - The manufacturing segment experienced a drastic revenue drop of 50.3% to RMB 7.741 billion, with a net loss of RMB 15.46 billion, attributed to significant impairments in specific investments [10]. Dividend and Share Buyback - The company has committed to a dividend of no less than HKD 1.5 billion for the fiscal year 2026, with plans to increase the payout ratio from 20% to 35% in the future [10]. - A share buyback program of up to HKD 1 billion has been initiated, alongside a commitment from major shareholders to increase their stakes by up to HKD 500 million, demonstrating management's confidence in the company's prospects [10].

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of HKD 48.24, based on a DCF valuation method [8][10]. Core Insights - The company focuses on the development of innovative therapies in the fields of metabolism, oncology, and liver fibrosis, with a strong emphasis on its core pipelines LAE102 and LAE002 [13][21]. - The ActRII pipeline is differentiated in its mechanism, showing superior safety and muscle gain effects, which could position it as a cornerstone therapy in weight loss when combined with GLP-1 drugs [8][26]. - The LAE002 pipeline addresses the issue of drug resistance in advanced breast cancer, with a successful licensing agreement with Qilu Pharmaceutical, validating its pipeline value [8][67]. Summary by Sections 1. Company Overview - The company was established in 2016 and went public on June 29, 2023, on the Hong Kong Stock Exchange, focusing on innovative therapies for metabolic diseases, cancer, and liver fibrosis [13][21]. 2. Metabolism Pipeline - The ActRII pipeline has shown promising results in muscle gain and fat loss, with LAE102 demonstrating significant improvements over existing treatments [8][36]. - Clinical data indicates that LAE102 can effectively reduce fat while preserving muscle mass, outperforming other small nucleic acid drugs in terms of muscle gain [57][58]. 3. Oncology Pipeline - LAE002 is a potent pan-AKT inhibitor that addresses drug resistance in advanced breast cancer, with a focus on HR+/HER2- subtypes, showing comparable efficacy to existing treatments but with better safety profiles [67][68]. - The company has completed patient enrollment for the Phase III clinical trial of LAE002, marking a significant milestone towards potential market entry [71]. 4. Financial Projections - Revenue projections for the company are expected to reach HKD 730 million in 2026, with a net profit forecast of HKD 400 million [1][8]. - The company anticipates significant growth in revenue, with a projected increase of 584.04% year-on-year in 2026 [1]. 5. Research and Development - The company has consistently increased its R&D spending, with projections of HKD 2.5 billion in 2025, reflecting its commitment to innovation and pipeline development [24][25].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported stable net profit on a comparable basis, with expectations for increased order demand driven by the upcoming World Cup [1] - The company demonstrated resilience in a challenging trade environment, with a slight decline in net profit attributed to one-time gains in the previous year [7] - The company maintains a strong cash reserve and a high dividend payout ratio, indicating financial stability [7] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2024: 28,663 million RMB (15% YoY growth) - 2025: 30,994 million RMB (8% YoY growth) - 2026E: 32,461 million RMB (5% YoY growth) - 2027E: 34,179 million RMB (5% YoY growth) - 2028E: 36,019 million RMB (5% YoY growth) [6] - Net profit forecasts are as follows: - 2024: 6,241 million RMB (37% YoY growth) - 2025: 5,825 million RMB (-7% YoY decline) - 2026E: 6,031 million RMB (4% YoY growth) - 2027E: 6,519 million RMB (8% YoY growth) - 2028E: 6,900 million RMB (6% YoY growth) [6] - The company has a projected PE ratio of 10 for 2026 and 9 for 2028, with a target market capitalization of 915 billion RMB, indicating a potential upside of 30% from the current market value [7] Revenue Structure Analysis - The revenue structure for the company in 2025 shows strong growth in leisure categories, with sales figures as follows: - Sports: 209.7 million RMB (+5.9% YoY) - Leisure: 84.1 million RMB (+16.7% YoY) - Underwear: 14.0 million RMB (-2.3% YoY) - Others: 2.1 million RMB (-3.4% YoY) [7] - Revenue by region indicates that the European and American markets outperformed China, with respective growth rates of +20.6% and +21.0% [7] - Major clients such as Uniqlo and Adidas have shown consistent growth, contributing significantly to overall revenue [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6]. Core Insights - The company reported a revenue of 12.91 billion HKD for 2025, representing a year-on-year increase of 46.9%. Adjusted profit reached 2.57 billion HKD, up 66.9%, and adjusted core profit was 2.81 billion HKD, reflecting a 77.8% increase. These results exceeded expectations [6]. - The company plans to continue expanding its store network and product categories in 2026, with an expected net profit of 3.22 billion HKD, a 3.5% increase year-on-year. The projected net profits for 2027 and 2028 are 3.86 billion HKD and 4.58 billion HKD, respectively, indicating growth rates of 20.1% and 18.5% [6][9]. - The company achieved a net increase of 3,647 stores in 2025, with a daily average GMV of 7,800 HKD per store, which is a 21.3% increase year-on-year. The total GMV for 2025 was 32.7 billion HKD, up 46.1% [7]. - The gross margin for 2025 was 33.0%, an increase of 2.43 percentage points year-on-year, driven by product structure optimization and improved supply chain efficiency. The net profit margin was 24.12%, up 7.14 percentage points [8]. - The company is expected to continue its channel penetration and store expansion strategy in 2026, with a focus on optimizing existing store locations and introducing new product categories [9]. Financial Summary and Valuation Metrics - Revenue projections for the upcoming years are as follows: 2026E at 16.04 billion HKD, 2027E at 19.50 billion HKD, and 2028E at 23.36 billion HKD, with year-on-year growth rates of 24.2%, 21.6%, and 19.8% respectively [11]. - The net profit projections are 3.22 billion HKD for 2026E, 3.86 billion HKD for 2027E, and 4.58 billion HKD for 2028E, with growth rates of 3.5%, 20.1%, and 18.5% respectively [11]. - The company’s P/E ratios are projected to be 18.5 for 2026E, 15.4 for 2027E, and 13.0 for 2028E, indicating a favorable valuation compared to its growth prospects [11].

Investment Rating - The report maintains a "Buy" rating for the company [2][7] Core Insights - The company's performance in 2025 was below market expectations, with a significant decline in net profit and core net profit, leading to a generous dividend payout with a dividend yield of 4.5% [7] - The company aims for a sales target of 100 billion in 2026, despite a 7.2% decline in sales amount in 2025 [7] - The company has a strong cash position and low financing costs, maintaining a green status under the "three red lines" policy [7] Financial Data and Profit Forecast - Revenue projections for the company show a decline from 86,457 million in 2025 to 83,518 million in 2026, with a year-on-year growth rate of -3.4% [6][8] - The net profit attributable to ordinary shareholders is expected to drop significantly to 61 million in 2026, reflecting a year-on-year growth rate of 10.5% [6][8] - The company’s cash position was 467.6 billion in 2025, with a total debt of 1,048 billion, indicating a stable financial structure [7]

Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics [2] Core Insights - Innovent Biologics achieved total revenue of RMB 13.0 billion in FY25, representing a year-on-year growth of 38%, with product sales revenue reaching RMB 11.9 billion, up 45% [3][15] - The company turned a net profit attributable to shareholders of RMB 810 million in FY25, compared to a loss of approximately RMB 100 million in the previous year [3][15] - The gross margin improved to 86.5%, an increase of 2.6 percentage points year-on-year [3][15] - The report highlights strong organic sales growth driven by the oncology franchise and the expansion of the product portfolio, with multiple products included in the National Reimbursement Drug List (NRDL) expected to further boost sales in 2026 [4][16] - Out-licensing revenue of RMB 957 million was recognized in FY25, with significant upfront payments from collaborations with Roche and Takeda expected to be progressively recognized in the financial statements from 2026 onward [5][17] - The core asset IBI363 (PD-1/IL-2) is advancing smoothly, with three assets entering global Phase III clinical trials, estimated to have a combined addressable market exceeding USD 60 billion [7][19] - The early-stage pipeline shows strong global competitiveness, with 11 new molecules advanced into clinical development, expected to yield early data in 2026-2027 [9][20] - The target price is adjusted to HKD 107.40 based on a DCF model, reflecting an increase in revenue and net profit forecasts for 2026 and 2027 [10][21]